A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating Sustained Response in Subjects With HBeAg Positive Chronic Hepatitis B Receiving Therapy With Pegasys (Peginterferon Alfa-2a) in Vietnam
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 03 Jul 2013 New trial record
- 01 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.